Inventor · disambiguated record
Haibo Qiu
Also filed as: QIU HAIBO
18 granted patents·16 pending applications·6 citations·filing 2007–2025
88Inventor score
Files withREGENERON PHARMA27ZHEJIANG HISUN PHARM CO LTD2QIU HAIBO1SHENZHEN MINDRAY BIOMEDICAL ELECTRONICS CO LTD1TENCENT TECH SHENZHEN CO LTD1
Top patents by PatentIndex Score
34 records- 0191US11371971B2High confidence compound identification by liquid chromatography-mass spectrometryREGENERON PHARMA·Filed 2021·Granted Jun 28, 2022·2 cites·20 claims
- 0288US11959897B2High confidence compound identification by liquid chromatography-mass spectrometryREGENERON PHARMA·Filed 2022·Granted Apr 16, 2024·1 cites·20 claims
- 0383US12259373B2High confidence compound identification by liquid chromatography-mass spectrometryREGENERON PHARMA·Filed 2024·Granted Mar 25, 2025·0 cites·20 claims
- 0483US12099042B2Use of liquid chromatography and mass spectrometry to characterize oligonucleotidesREGENERON PHARMA·Filed 2021·Granted Sep 24, 2024·1 cites·28 claims
- 0579US12196761B2Use of LC-MS/MS to quantitate protein biomarkersREGENERON PHARMA·Filed 2023·Granted Jan 14, 2025·0 cites·8 claims
- 0679US2025060346A1Use of liquid chromatography and mass spectrometry to characterize oligonucleotidesREGENERON PHARMA·Filed 2024·Application pending·0 cites
- 0777US11592449B2Use of LC-MS/MS to quantitate protein biomarkersREGENERON PHARMA·Filed 2019·Granted Feb 28, 2023·1 cites·18 claims
- 0877US2025035643A1Unbiased and high-throughput identification and quantification of host cell protein impurities by automated iterative lc-ms/ms (hcp-aims) for therapeutic protein developmentREGENERON PHARMA·Filed 2024·Application pending·0 cites
- 0976US12280070B2Drugs for prevention or treatment of sepsisUNIV SOUTHEAST·Filed 2024·Granted Apr 22, 2025·0 cites·3 claims
- 1075US11674968B2Methods for identifying free thiols in proteinsREGENERON PHARMA·Filed 2020·Granted Jun 13, 2023·1 cites·22 claims
- 1172US2023273216A1Methods for identifying free thiols in proteinsREGENERON PHARMA·Filed 2023·Application pending·0 cites
- 1271US12436152B2Methods for predicting and modulating glycation of a proteinREGENERON PHARMA·Filed 2022·Granted Oct 7, 2025·0 cites·10 claims
- 1371US2025231191A1Lc-ms methods for antibody isotyping and quantificationREGENERON PHARMA·Filed 2025·Application pending·0 cites
- 1468US12153053B2Unbiased and high-throughput identification and quantification of host cell protein impurities by automated iterative LC-MS/MS (HCP-AIMS) for therapeutic protein developmentREGENERON PHARMA·Filed 2021·Granted Nov 26, 2024·0 cites·36 claims
- 1567US12411141B2LC-MS methods for antibody isotyping and quantificationREGENERON PHARMA·Filed 2020·Granted Sep 9, 2025·0 cites·50 claims
- 1664US2024418730A1Host cell protein analysis for adeno-associated virus (aav)-based gene therapyREGENERON PHARMA·Filed 2024·Application pending·0 cites
- 1763US2025164488A1Structure and function characterization of adeno-associated virus (aav) by hdx-msREGENERON PHARMA·Filed 2024·Application pending·0 cites
- 1861US2024337664A1Characterization of crosslinking sites in antibody-drug conjugatesREGENERON PHARMA·Filed 2024·Application pending·0 cites
- 1961US2024053359A1Native microfluidic ce-ms analysis of antibody charge heterogeneityREGENERON PHARMA·Filed 2023·Application pending·0 cites
- 2060US2023279046A1Size exclusion chromatography for characterizing host cell proteinsREGENERON PHARMA·Filed 2023·Application pending·0 cites
- 2160US2023408527A1Methods for characterizing host-cell proteinsREGENERON PHARMA·Filed 2023·Application pending·0 cites
- 2258US2022332849A1Stabilized Formulations Containing Anti-MUC16 x Anti-CD3 Bispecific AntibodiesREGENERON PHARMA·Filed 2022·Application pending·0 cites
- 2358US2025314669A1Methods and systems for characterizing metal interactions in antibody samplesREGENERON PHARMA·Filed 2025·Application pending·0 cites
- 2457US2023043610A1Native microfluidic ce-ms analysis of antibody charge heterogeneityREGENERON PHARMA·Filed 2022·Application pending·0 cites
- 2556US2023166199A1Methods for characterizing host-cell proteinsREGENERON PHARMA·Filed 2022·Application pending·0 cites
- 2655US12169199B2Activity based host cell protein profilingREGENERON PHARMA·Filed 2021·Granted Dec 17, 2024·0 cites·29 claims
- 2755US12169203B2Native microfluidic CE-MS analysis of antibody charge heterogeneityREGENERON PHARMA·Filed 2020·Granted Dec 17, 2024·0 cites·20 claims
- 2853US12469248B2Method, apparatus, device, and storage medium for training image processing modelTENCENT TECH SHENZHEN CO LTD·Filed 2022·Granted Nov 11, 2025·0 cites·20 claims
- 2949US12172106B2Methods for assessing binding affinity of an antibody variant to the neonatal Fc receptorREGENERON PHARMA·Filed 2019·Granted Dec 24, 2024·0 cites·23 claims
- 3049US2023373972A1Piperazine derivative, preparation method therefor and use thereofZHEJIANG HISUN PHARM CO LTD·Filed 2021·Application pending·0 cites
- 3147US12447151B2Alkyne derivative, preparation method for same, and uses thereofZHEJIANG HISUN PHARM CO LTD·Filed 2020·Granted Oct 21, 2025·0 cites·9 claims
- 3247US12420044B2Respirator and ventilation control method thereforSHENZHEN MINDRAY BIOMEDICAL ELECTRONICS CO LTD·Filed 2020·Granted Sep 23, 2025·0 cites·10 claims
- 3347US2022218928A1Method for evaluating volume responsiveness and medical deviceZHONGDA HOSPITAL SOUTHEAST UNIV·Filed 2022·Application pending·0 cites
- 3438US8520239B2Printing control method and apparatus of a printing process with different working stagesQIU HAIBO·Filed 2007·Granted Aug 27, 2013·0 cites·11 claims
Join the waitlist — get patent alerts
Get an alert when Haibo Qiu files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →